1. Introduction {#s0005}
===============

The initial immune response to infection by a wide range of pathogens triggers a set of stereotyped clinical manifestations including fever, fatigue, hypersomnia, hyperalgesia, anorexia, disturbed mood, and cognitive difficulties -- termed the acute sickness response. The changes in physiology and behaviour which characterise the acute sickness response are also well documented in a wide range of vertebrate species indicating strong evolutionary conservation of the phenomenon ([@b0075], [@b0095]). This response is initiated in the periphery by elements of the activated immune system, and is mediated by the action of pro-inflammatory cytokines and other acute phase proteins. The acute sickness response is ultimately translated into central nervous system events via activation of resident microglial cells, secondary production of mediators, and ultimately altered neural transmissions ([@b0200]).

We have previously shown that during the acute sickness response, the severity of the illness correlates with the production of pro-inflammatory cytokines in the periphery ([@b0205]). However, in relation to any given acute infection, the illness manifestations cannot simply be equated to the acute sickness response, as the symptoms and signs are also attributable to local pathogen-mediated tissue injury. For example in primary *Varicella-zoster Virus* (VZV) infection, the vesicular skin rash is due to viral replication and cytolysis of epithelia and other skin cells, as well as local immunopathology ([@b0230]), whereas the systemic features of chickenpox such as fever, loss of appetite, and malaise are likely to be purely immunologically driven.

Although the acute sickness response consists of a relatively uniform set of symptoms and behaviours, it is very evident in clinical practice that there is significant variability in the frequency and severity of specific illness manifestations experienced by one individual in comparison to another during acute infection with the same pathogen, including infection with microorganisms which do not feature significant genetic variability. This is illustrated by case series of patients with Severe Acute Respiratory Syndrome (SARS) in which the reported prevalence of systemic illness manifestations such as myalgia, range from 7% to 50% ([@b0045], [@b0150]), and approximately 30% of patients report chills and rigors, whereas the remainder do not ([@b0020], [@b0220], [@b0045], [@b0150]). As analysis of variability in the genome of the SARS Corona virus (SARS CoV), has revealed very limited alterations between isolates ([@b0175], [@b0180]), it is unlikely that these variations in individual symptoms relate to changes in the pathogen.

We have previously found that the overall *severity* of the acute sickness response to several different pathogens is associated with functional polymorphisms in pro-inflammatory cytokine genes ([@b0210]), indicating a strong host genetic influence on the response. Given the observed variations within the detailed pattern of the acute sickness response to a given pathogen, we therefore sought to test the hypothesis that the pathophysiological basis of relatively discrete 'symptom domains' within the overall illness complex may also be differentially influenced by genetic polymorphisms. This notion of symptom domains is analogous to the concept of 'endophenotypes', which arose relatively recently out of the substantive challenges of pathophysiological research into the common, complex, and heritable disorders of mental health, including major depression and bipolar disorder ([@b0030]). The intent of this concept was to divide behavioural symptoms into recognisable and stable characteristics with a likely (or proven) genetic association. The assumptions underlying the concept are firstly that genes influencing susceptibility to mental disorders are likely to be mediated via multiple neurotransmitter systems affecting multiple neurobehavioural processes such as attention, memory, stress sensitivity, and emotional regulation ([@b0025]); and secondly, that identification of genetic or other biological correlates with an endophenotype is likely to be less complex than that of the illness phenotype overall ([@b0060]). Although this field is still in its infancy, one of the best examples is in the context of studies of suicidal behaviour, in which impulsive--aggressive behaviour is an endophenotype, and with which polymorphisms in the serotonin receptor-1B gene (5-HT~1B~) have been associated ([@b0225]).

In this study, the endophenotype concept has been applied to comprehensive clinical datasets describing symptom domains of the acute sickness response associated with both viral and non-viral pathogens from a prospective cohort study of infection outcomes ([@b0080])and validation of the endophenotypes was completed by demonstration of associations with functional polymorphisms in cytokine genes.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

A total of 296 unambiguously Caucasian, adult subjects \[mean age 34.2 years, 49% women\], with complete data sets, were selected from participants in the Dubbo Infection Outcomes Study (DIOS, *N*  = 396) ([@b0080]). Subjects were recruited into DIOS, after written informed consent, subsequent to presentation to their family physician and serological testing indicated acute Epstein Barr Virus (EBV), Ross River Virus (RRV), or Q fever infection. All participants were recruited shortly after the acute febrile phase of their illness, and no greater than 6 weeks after the onset of symptoms. The relevant institutional review boards approved this study.

2.2. Self-report measures {#s0020}
-------------------------

After enrolment participants were followed up at 2--3 weeks, 4--6 weeks, and at three monthly intervals thereafter until 12 months post infection. At enrolment, the study nurse conducted a baseline medical and psychiatric interview and recorded the date of onset of symptoms, as well as demographic characteristics including a detailed description of the subject's ethnicity. At each visit a wide range of physical and psychological symptoms of acute illness were assessed using two self-administered questionnaires; the Somatic and Psychological Health Report (SPHERE) ([@b0090]) and the Physical Symptoms Checklist (PSC) ([@b0080]) -- (see online [Supplementary material](#s0105){ref-type="sec"} for copies of the questionnaires). The impact of the illness on functional capacity was recorded at each time point using the Brief Disability Questionnaire ([@b0215]).

2.3. Endophenotype indices {#s0025}
--------------------------

Principal components analysis (PCA) of baseline symptom data collected by the SPHERE and PSC (51 symptom items) was used to derive indices of the individual symptom domains or endophenotypes of the acute sickness response. An initial analysis of symptom question items with a report rate \>30% revealed that the items fell into four broad symptom domains: *pain*, *fatigue*, *neurocognitive difficulties*, and *mood disturbance*. Items relevant to each endophenotype were further selected by face validity and included in the initial PCA for each domain. For symptom items which were duplicated (e.g., SPHERE Q1 -- 'headache' and PSC Q7 -- 'had a headache'), the item with the lower loading score on the first component in the PCA was removed. The initial PCAs were then refined by sequential removal of non-salient (loading score \<0.4) symptom items and ensuring that the first component accounted for \>30% of the variance. The optimal solutions contained items uniquely relevant to the designated symptom domain: *mood disturbance* -- 6 items (SPHERE Q's 2, 7, 18, 19, 20, 21, 24, 34), *pain*-8 items (SPHERE Q's 4, 5, 10, 11, 12, 31; PSC Q's 9, 10), *fatigue* -- 6 items (SPHERE Q's 6, 13, 14, 15, 26; PSC Q15), and *neurocognitive difficulties* -- 3 items (SPHERE Q's 3, 16, 27) (see online [Supplementary material](#s0105){ref-type="sec"} for individual item loading scores).

2.4. Illness severity index {#s0030}
---------------------------

The baseline symptom data collected by the SPHERE and PSC were also used to derive an overall index of illness *severity* by PCA in order to relate the contribution of the individual symptom domains to the illness complex as a whole. In preliminary data preparation, symptom items with a low report rate (\<30%) were excluded (17 items). PCA was then conducted on the remaining 34 symptom items. In determining the optimal solution symptom items were then sequentially removed until all remaining items had a loading score \>0.4 (salient variables) and the first component accounted for \>30% of the variance, allowing for an index based on 25 items which encapsulated a spectrum of severity (see online [Supplementary material](#s0105){ref-type="sec"} for individual item loading scores).

2.5. Selection of comparison groups {#s0035}
-----------------------------------

One hundred subjects with scores constituting the top and bottom thirds of the distribution of the empirically-derived symptom domains were selected to optimally represent the extremes of each domain. Subjects with equivalent scores at the cut-off (*N*  = 100) were included into the respective extreme. The comparison groups were labelled for subsequent analysis as 'high' -- to represent a high symptom endophenotype and as 'low' to represent the low symptom endophenotype.

2.6. Duration of illness {#s0040}
------------------------

The SOMA subscale of the SPHERE which records somatic symptoms ([@b0065]), was used to measure illness duration ([@b0080]). A conservative measure of illness duration was designated as the time in days of continuous SOMA positivity (score ⩾3 out of a possible 12) from the symptom onset date plus half the time between the last SOMA positive date and first SOMA negative (\<3) date. Illness duration was not derived for 18 subjects due to incomplete longitudinal data sets.

2.7. DNA extraction and genotyping {#s0045}
----------------------------------

DNA was extracted from peripheral blood mononuclear cells (PBMCs) (Wizard DNA kit; Promega) and quantified using NanoDropR ND-1000 (Biolab), before the quality was verified by agarose gel electrophoresis. Genomic DNA was sent to the Australian Genome Research Facility (AGRF) for genotyping by Sequenom MassARRAY® of functional polymorphisms in pro- and anti-inflammatory cytokines implicated in the acute sickness response, including interferon (IFN)-γ (rs2430561), tumour necrosis factor (TNF)-α (rs1800629) and IL-6 (rs18000795) genes, as well as interleukin (IL)-10 (rs1800896 and rs1800872).

2.8. Statistical analysis {#s0050}
-------------------------

Statistical analyses were performed using SPSS for Windows version 15 (SPSS Inc., Chicago, IL, USA). Factor analysis (principal component method) was used to derive the illness severity and symptom domain (endophenotype) indices. Multiple regression analysis was used to demonstrate independence of the overall sickness response from age, sex and infection type. Logistic regression analyses then served to determine the relative impact of specific cytokine genotypes and endophenotype outcomes with relevant covariates (age, sex, and infection type) included in the models.

Correlation analyses were used to assess bi-variate relationships. Analyses of the consistency of the endophenotype-scores over time (referred to as temporal stability) was additionally examined via intraclass correlation coefficients. Statistical significance was set at *p*  \< 0.05.

3. Results {#s0055}
==========

3.1. Symptom domains of the acute sickness response {#s0060}
---------------------------------------------------

Four symptom domains, or endophenotypes, within the illness complex were derived by PCA. Within each symptom domain, comparison groups were derived to optimally represent the extremes (the top and bottom tertiles) of the distribution of the PCA scores. [Table 1](#t0005){ref-type="table"} summarises the characteristics of the extreme groups.Table 1Characteristics of subjects in the high and low extreme groups for each of the symptom domains.SeverityFatiguePainMood disturbanceNeurocognitive difficultiesHighLowHighLowHighLowHighLowNo. of subjects100102100102100100104130Mean age in years (±SD)32.3 (14.6)37.4 (16.1)36.1 (13.2)32.5 (15.8)31.7 (13.3)36.5 (15.9)33.5 (14.4)35 (15.4)M:F ratio45:5463:3252:4849:4242:5859:3444:5976:47Infection type (EBV:RRV:QF)51:23:2637:41:2434:40:2660:13:3054:21:2545:31:2449:23:3257:43:30

3.2. Severity of the acute sickness response {#s0065}
--------------------------------------------

The principal component reflecting the overall illness severity featured the fundamental symptoms of the acute sickness response (e.g., fatigue, musculoskeletal pain, cognitive disturbance, sleep disturbance). Multiple regression analysis of the scores verified that the index was not predicted by age, sex or infection type ($R_{\text{adj}}^{2}$  = 0.012, *F*(3.281) = 2.11, *p*  = 0.1). Two disability measures from the BDQ questionnaire were used to validate the illness severity index. Positive correlations were found between the illness *severity* score and the reported 'number of days spent in bed' (*r*(225) = 0.121, *p*  = 0.001), and 'number of days spent away from usual activities' (*r*(224) = 0.33, *p*  \< 0.001).

3.3. Relative severity of symptom domains {#s0070}
-----------------------------------------

Initial validation of the individual symptom domain indices was sought by correlation of the sum of these indices with the overall illness *severity* scores for each subject. Spearman's correlations between the percentile ranks for each subject in illness *severity* and the summed percentile ranks of the symptom domains revealed a strong correlation (*r* ~s~(294) = 0.971, *p*  \< 0.0001). The summed endophenotype scores correlated with the measures of disability including 'number of days spent in bed' (*r*(225) = 0.20, *p*  = 0.002), and 'number of days spent away from usual activities' (*r*(224) = 0.31, *p*  \< 0.001).

Further investigation of the composition of the illness complex revealed several interesting findings. As depicted in [Fig. 1](#f0005){ref-type="fig"} , the overall illness *severity* varied between subjects with the same infection, as well as across infection sub-cohorts. Secondly, within a given infection group, although overall illness *severity* may have been comparable in some subjects, the relative contributions from the individual symptom domains making up the illness complex varied between these subjects.Fig. 1Relative severity of symptom domains of the acute sickness response. Summed rank scores of the four individual symptom domains demonstrated variations in overall illness *severity*, as variations in the relative severity of individual symptom domains between subjects within the one infection group. For instance, RRV subjects 2 and 3 have comparable overall illness *severity* as well as comparable severities for each of the symptom domains. By contrast, EBV subjects 2 and 3, and QF subjects 2 and 3 have comparable overall illness *severity*, but varied severities the of the individual symptom domains which make up the illness complex.

3.4. Temporal stability of symptom patterns {#s0075}
-------------------------------------------

The observed variation in the severity of individual symptom domains, suggested that each individual's acute sickness response may be dominated by one or more symptom domains over another. If this is host determined, in subjects with prolonged illness this may be expected to be temporally stable. To investigate this notion, indices for all subjects (*N*  = 168) for whom data were available for at least 3 months were derived at 2 weeks, 6 weeks, and 3 months post enrolment. The relative severity and stability of each symptom domain is illustrated in four subjects with persisting symptoms in [Fig. 2](#f0010){ref-type="fig"} . [Fig. 2](#f0010){ref-type="fig"}A reveals an 'equally' distributed illness complex which was stable over time; while [Fig. 2](#f0010){ref-type="fig"}B--D show illness responses that were dominated by *pain*, *mood disturbance*, and *fatigue* respectively. The stability of symptom dominance across time for each endophenotype was reflected by significant correlations in scores from adjacent assessment points. In addition, the overall consistency of scores within endophenoptypes across all time points was evidenced by significant intraclass correlations (see [Table 2](#t0010){ref-type="table"} for both).Fig. 2(A--D) Temporal stability of dominant symptom domains. The four stacked column graphs illustrate stable patterns of symptom domain dominance in selected subjects with prolonged illness after acute infection, including an equally distributed symptom complex (A), and symptom complexes dominated by *pain* (B), *mood disturbance* (C), and *fatigue* (D).Table 2Consistency measures for scores obtained for each of the symptom domains across four assessment times (*N* = 168).FatiguePainMood disturbanceNeurocognitive difficulties*rrrr*Baseline--week 20.600.660.600.50Week 2--week 60.700.760.800.63Week 6--3 months0.610.670.620.58ICC (95% CI)0.56 (0.49--0.64)0.62 (0.55--0.69)0.55 (0.47--0.63)0.47 (0.40--0.56)[^1][^2]

3.5. Association of cytokine genotypes with symptom domain severity {#s0080}
-------------------------------------------------------------------

Genotypes for all candidate SNPs were in Hardy--Weinberg equilibrium (all *p*  \> 0.2). Regression modelling to predict extreme scores in the *fatigue* domain produced a highly significant solution \[*χ* ^2^(5) = 30.1; *p*  \< 0.001\] which indicated that the putative high cytokine producing T allele of the IFN-γ +874 T/A SNP was the best predictor of severe fatigue \[*p*  \< 0.001; OR: 3.6 (95% confidence interval (CI): 1.8--7.2\]. In addition, females were more likely grouped in the high fatigue extreme \[*p*  = 0.01; OR: 2.3 (95% CI: 1.2--4.6\], while individuals with RRV infection were less likely to suffer from extreme fatigue \[*p*  = .02; OR: 0.35 (95% CI: 0.15--0.85\]. The best solution for extreme scores in the pain symptom domain \[*χ* ^2^(5) = 21.6; *p*  = 0.001\] identified RRV infection as the best and only predictor for high pain severity \[*p*  = 0.004; OR: 3.5 (95% CI: 1.5--8.1\]; this model also included the IL-6 SNP, however the association with the high producing G allele failed to reach significance (*p*  = 0.08).

The model for *neurocognitive difficulties* \[*χ* ^2^(5) = 21.6; *p*  = 0.001\] showed that female sex was the strongest predictor for neurocognitive difficulties during acute illness \[*p*  = 0.001; OR: 2.9 (95% CI: 1.6--5.4\]. In contrast, subjects homozygous for the high producing C allele of the IL-10 −592 C/A SNP were significantly less likely to experience *neurocognitive difficulties* \[*p*  = 0.005; OR: 0.44 (95% CI: 0.25--0.78\], as were those with RRV infections \[*p*  = 0.03; OR: 0.42 (95% CI: 0.19--0.90\]. The best solution for severe symptoms in the mood domain \[*χ* ^2^(6) = 29.1; *p*  \< 0.001\] also identified female sex as the strongest risk for severe mood disturbance during acute infection \[*p*  \< 0.001; OR: 3.9 (95% CI: 1.9--7.9\]. This model included both the IL-6 −174 G/C and the IL-10 −592 C/A SNPs. The putative high producing G allele of the IL-6 −174 G/C SNP was associated with greater mood disturbance \[*p*  = 0.027; OR: 2.2 (95% CI: 1.1--4.4\], while the IL-10 −592 C allele exerted a protective effect \[*p*  = 0.014; OR: 0.44 (95% CI: 0.23--0.85\]. Moreover, those individuals who had both the G allele of the IL-6 −174 and an A allele for IL-10 −592 (i.e., a high IL-6 low IL-10 combination) had a greatly increased risk for mood disturbance \[*p*  = 0.004; OR: 5.3 (95% CI: 1.7--16.2\].

No other allelic combinations were associated with an increase in the strength of the association with the endophenotypes.

4. Discussion {#s0085}
=============

This is the first systematic phenotypic and immunogenetic analysis of the different components of the acute sickness response in the setting of natural infection in humans. The illness *severity* phenotype described here was ubiquitous across infection types, yet also highlighted heterogeneity within the varied pattern and duration of the response. This heterogeneity was further explored via empirically-derived indices describing endophenotypes or symptom domains within the overall illness complex. These indices were validated by demonstration of significant differential associations with polymorphisms in cytokine genes previously implicated in the acute sickness response ([@b0210]).

As expected, there was a robust correlation between illness *severity* and the level of reported disability in the acute illness, supporting the validity of this measure in the clinical setting. Consistent with previous analyses in the DIOS cohort ([@b0080], [@b0210]), the illness *severity* phenotype was not dependent on age, sex or infection subtype. This finding is concordant with the recognised spectrum of clinical illness severity for each of the pathogens studied here. Infectious mononucleosis due to primary EBV infection occurs in 25--50% of adolescents and adults who become infected -- the remainder have mild or subclinical illness ([@b0195]); similarly the subclinical: clinical ratio for RRV infection ranges from 1.2--3.0 ([@b0235]); and almost 60% of QF infection cases in adults are asymptomatic ([@b0140]).

It is also evident in clinical practice that there is significant variability in the pattern of symptoms experienced by one individual in comparison to another during acute infection with the same pathogen. For example, in infectious mononucleosis due to EBV infection the prevalence of sore throat, headache and malaise ranged from 70--88%, 37--55%, and 43--76%, respectively across several studies ([@b0135], [@b0155], [@b0130]). Consistent with these observations, when the acute sickness response was systematically divided into symptom domains, it became evident that the prevalence and severity of each endophenotype varied between subjects infected with the same pathogen.

Although the illness complex as a whole and its *severity* were independent of demographics, females were over-represented in the high severity groups for *fatigue*, *neurocognitive difficulties*, and *mood disturbance*. This finding is consistent with previous studies showing that women are more likely to report both physical and psychological symptoms than men ([@b0055], [@b0010]), with one study demonstrating that most physical symptoms are typically reported at least twice as commonly by women in a healthy, disease-free setting ([@b0100]). It has been proposed that as a result of their reproductive role, women are more attentive to bodily changes ([@b0055], [@b0010]), and/or have heightened interoceptive awareness which allows them to sense internal disruptions more easily; and may thus be more likely to report symptoms ([@b0055], [@b0010]). Gender socialisation roles may additionally impact on this phenomenon ([@b0055], [@b0010]). Interestingly, although no sex difference in seroprevalence or clinical illness rates are reported for EBV, men are more commonly symptomatic with acute QF than women (at a ratio of 2.5:1), despite equal seroprevalence ([@b0185]). Studies in a mouse model of QF suggest this may be attributable to the effects of oestrogens on the host response ([@b0120]).

Administration of recombinant cytokines, or activation of cytokine production by immunogenic stimulation (e.g., via administration of lipopolysaccharide) produces the symptom complex characteristic of the acute sickness response ([@b0035]). In particular, the pro-inflammatory cytokines, IL-1β, IL-6, and TNF-α have been most studied and each shown to induce fever, fatigue, anhedonia, anorexia, depressed mood and to perturb cognitive functions. On the other hand, the anti-inflammatory cytokine, IL-10 has been shown to inhibit the symptoms of the acute sickness response ([@b0105]). In our previous study in DIOS demonstrated strong correlations between symptom severity during the acute illness and *ex vivo* production of IL-1β and IL-6 ([@b0205]). In particular, symptoms of mood disturbance were associated with IL-6 production, whereas fatigue and other physical symptoms were better correlated with IL-1 production, raising the suggestion that individual cytokines may influence the generation of different components of the symptom complex.

We have previously shown significant associations between more severe acute infective illness and protracted illness duration, with polymorphisms in the IFN-γ and IL-10 genes ([@b0210]). The data presented here specifically implicate the high-producing T allele of the IFN-γ gene in the production of *fatigue*. This allele is associated with increased binding of transcription factors to a putative NF-κB site ([@b0160], [@b0165]), resulting in increased cytokine production. Patients undergoing treatment with recombinant IFN-γ report symptoms typical of the acute sickness response, although only fever, headaches and chills, but not self-reported fatigue or other symptoms have been found to be more frequent in the treated subjects than those receiving placebo in controlled trials ([@b0050], [@b0170]). However, only brief self-report items, rather than systematic delineation of symptom domains, was undertaken in the adverse event reporting in these trials.

We have also previously shown a significant association between the A allele of the IL-10 −592 C/A SNP with increased illness *severity*. In the present study further associations were demonstrated with greater *mood disturbance* and increased *neurocognitive difficulties*. The A allele of this SNP has been associated with decreased production of IL-10 and a bias towards pro-inflammatory responses ([@b0190], [@b0115]). IL-10 knockout mice feature a worsened acute sickness response upon challenge with lipopolysaccharide, notably increased 'fatigue' evidenced by reduced psychomotor coordination in a running test and shortened time to volitional fatigue ([@b0105]). In addition, increased 'depression-like' changes in behaviour has been observed in these mice, evidenced by decreased latency to immobility and longer immobilization periods in a forced swimming test -- changes that were reversible by the administration of IL-10 ([@b0145]).

Carriers of the allele correlating with increased production of IL-6 (−174 G) had greater *mood disturbance* in the data reported here*.* This finding is particularly interesting as a substantive body of literature has documented elevated serum levels of IL-6 in patients with major depression ([@b0125], [@b0110], [@b0015], [@b0040]). In combination these data suggest shared mechanisms underpinning both the typically short-lived mood disturbance in the context of acute infection, and the more substantive and sustained phenomenon of major depression.

We have documented significant and synergistic effects of a genetically-determined imbalance in pro- and anti-inflammatory cytokine production on the severity and duration of the acute sickness response ([@b0210]). In the present study, this synergistic association was only evident in relation to *mood disturbance* and the lL-6/IL-10 SNP combination, potentially suggesting that the other endophenotypes are more specifically associated with individual cytokines.

The systematic analysis of the spectrum of symptoms of the acute sickness response described here supports the concept of a universal, yet somewhat heterogeneous, host phenomenon made up of coherent, temporally stable symptom domains or endophenotypes. Further exploration of the genetic associations with these endophenotypes is likely to provide unique insights into the more sustained and severe disorders which feature similar symptoms, including post-infective fatigue syndrome and major depression.

Appendix A. Supplementary data {#s0105}
==============================

Supplementary data 1
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[^1]: *r* = Pearson correlations, ICC = intraclass correlation coefficient; CI = confidence interval.

[^2]: *P* values for all statistics presented in this table are \<0.001.
